Pfizer CEO: Transforming Drug Discovery, Lessons from China and Leading with Optimism
Episode
48 min
Read time
2 min
Topics
Productivity, Health & Wellness, Fundraising & VC
AI-Generated Summary
Key Takeaways
- ✓ADC Oncology Platform: Antibody-drug conjugates function like GPS-guided missiles — the antibody targets specific tissue, the drug payload delivers treatment only at that site. Pfizer's Seagen acquisition brought 4 marketed ADC products and 13 clinical-stage candidates. Swapping antibodies or payloads creates combinatorial opportunities across cancer types, from liver to brain to bone.
- ✓R&D Focus Over Capability: Pfizer's clinical success rate is 19% versus the industry average of 11%, with phase two success rates above 50% compared to the industry's 25-30%. The core problem wasn't scientific capability — it was choosing commercially undervalued targets. Fixing focus through governance and leadership changes takes months, not the 5-7 years a capability rebuild would require.
- ✓China Biotech Threat: Chinese universities now hold 8 of the top 10 spots in the Nature Index scientific rankings, up from near zero recently. Chinese biotech operates at three times the speed and half the cost of Western peers. Bourla estimates China will surpass Western firms in early-stage drug discovery within two years, following the same trajectory as EVs and solar panels.
- ✓Decentralized AI Accountability: Rather than centralizing AI in one expert team, Pfizer assigns transformation accountability directly to business unit leaders — manufacturing, research, commercial — while the center provides infrastructure, data, and computing. Leaders must deliver measurable transformation plans. Pfizer is building a three-tier AI certification system: fluent, proficient, and expert, with thousands currently enrolled.
- ✓Organizational Confidence as Asset: After COVID revenues dropped from $56B in 2022 to $6B, Pfizer used the resilience built during vaccine development to recover. Leaders should actively surface and amplify internal success stories to counteract the natural organizational bias toward focusing on failures, as collective confidence built through visible wins directly accelerates subsequent performance recovery.
What It Covers
Pfizer CEO Albert Bourla discusses the company's strategic transformation under his leadership since 2019, covering $80B+ in acquisitions including ADC oncology platform Seagen, the China biotech threat, AI-driven drug discovery, and how organizational culture and confidence drive pharmaceutical performance.
Key Questions Answered
- •ADC Oncology Platform: Antibody-drug conjugates function like GPS-guided missiles — the antibody targets specific tissue, the drug payload delivers treatment only at that site. Pfizer's Seagen acquisition brought 4 marketed ADC products and 13 clinical-stage candidates. Swapping antibodies or payloads creates combinatorial opportunities across cancer types, from liver to brain to bone.
- •R&D Focus Over Capability: Pfizer's clinical success rate is 19% versus the industry average of 11%, with phase two success rates above 50% compared to the industry's 25-30%. The core problem wasn't scientific capability — it was choosing commercially undervalued targets. Fixing focus through governance and leadership changes takes months, not the 5-7 years a capability rebuild would require.
- •China Biotech Threat: Chinese universities now hold 8 of the top 10 spots in the Nature Index scientific rankings, up from near zero recently. Chinese biotech operates at three times the speed and half the cost of Western peers. Bourla estimates China will surpass Western firms in early-stage drug discovery within two years, following the same trajectory as EVs and solar panels.
- •Decentralized AI Accountability: Rather than centralizing AI in one expert team, Pfizer assigns transformation accountability directly to business unit leaders — manufacturing, research, commercial — while the center provides infrastructure, data, and computing. Leaders must deliver measurable transformation plans. Pfizer is building a three-tier AI certification system: fluent, proficient, and expert, with thousands currently enrolled.
- •Organizational Confidence as Asset: After COVID revenues dropped from $56B in 2022 to $6B, Pfizer used the resilience built during vaccine development to recover. Leaders should actively surface and amplify internal success stories to counteract the natural organizational bias toward focusing on failures, as collective confidence built through visible wins directly accelerates subsequent performance recovery.
Notable Moment
Bourla's mother, a Holocaust survivor who was pulled from a firing squad at the last moment through bribed German soldiers, never expressed hatred toward her captors. She framed survival purely as celebration of possibility — a mindset she passed directly to Bourla that shapes his leadership philosophy today.
Episode Transcript
Hi, everyone, and, welcome to In Good Company. I'm, Nikolai Tangen, the head of the Norwegian sovereign wealth fund. And today, I'm in particularly good company because I'm here with Albert Gorla, who is the chairman and CEO of Pfizer, one of the largest pharma companies in the world. Now, Alberto has been with Pfizer for thirty years, been CEO since 2019, and has led the company through a remarkable period of change. Warm welcome. Thank you very much. And so, you know, I'm with Pfizer thirty three years. I'm with my wife. I'm with my wife thirty. Alright. I I got it mixed up there, Evan. Yes. Yeah. Now a lot of stuff has happened since you took over as, CEO. What what are you most excited about just now? I think, I'm always excited, by by the future, like all CEOs. Right? They see the the opportunities ahead. And, science is at the highest levels we ever had it, and science is affecting our business, very big time. So I'm very, very optimistic about the scientific progress that we can see in the next, years until the end of the decade. You sharpened the focus on innovative medicine, sold off consumer health care and so on. Why did you think that was the right decision to make? I'm a believer about, you know, corporations' role is not to heads. It is, to be very good, a few things. Investors role is to head. So I believe that requires different culture for a scientific company and different culture for a consumer company and very different culture for an of patent generic company. So I felt that, we should choose to be good at what it is really important, and that was science. Now we're not going to spend much time on on COVID, but we have to just touch on the fact that you did an unbelievable job, put a a huge amount of your own capital in there and produced a vaccine in eight months. Just how was that possible? Well, you know, it was the possible, for several reasons, but the most important is was exceptional times. So everybody felt that this is the culture of society, our civilization is at it's at risk. So everybody gave everything. And when I say everybody, I mean the government, I mean the our people, I mean, our hospitals that corroborated. Mhmm. So it was not easy to be done without them being aligned. Why don't we continue to work this way at full speed? Because, we don't have this big need that, is driving people's behaviors and they have the tendency to go back to the old habits. I have seen that with regulators, but after being extremely, instrumental in being able to achieve what we achieved, they became back to more conservative. I have seen that with the government operations that were opening the ways to to us to be able to accomplish what we accomplished and now …
Get the full transcript (7,525 words) + summary by email — free
One-time email with the complete transcript and AI summary of this episode. No account needed.
One email, no spam. We’ll also show you what SignalCast does.
Browse all In Good Company with Nicolai Tangen transcripts →
You just read a 3-minute summary of a 45-minute episode.
Get In Good Company with Nicolai Tangen summarized like this every Monday — plus up to 2 more podcasts, free.
Pick Your Podcasts — FreeKeep Reading
More from In Good Company with Nicolai Tangen
Ørsted CEO: Offshore Wind's Boom and Bust, America's Pushback and Rebuilding Trust
Aug 19 · 49 min
a16z Podcast
Ben Horowitz and Travis Kalanick on Building Again
Aug 14
More from In Good Company with Nicolai Tangen
Bonus: Advice to young people
Aug 11 · 14 min
No Priors: Artificial Intelligence | Technology | Startups
Scaling Global Organizations in the Age of AI with ServiceNow CEO Bill McDermott
Apr 17
More from In Good Company with Nicolai Tangen
We summarize every new episode. Want them in your inbox?
Ørsted CEO: Offshore Wind's Boom and Bust, America's Pushback and Rebuilding Trust
Bonus: Advice to young people
HIGHLIGHTS: Susan Cain
Susan Cain: Why Introverts Make Great Leaders, Staying Human in the AI Age and the Bittersweet Life
Bonus: How do CEO’s stay fit?
Similar Episodes
Related episodes from other podcasts
a16z Podcast
Aug 14
Ben Horowitz and Travis Kalanick on Building Again
No Priors: Artificial Intelligence | Technology | Startups
Apr 17
Scaling Global Organizations in the Age of AI with ServiceNow CEO Bill McDermott
a16z Podcast
Feb 16
Novartis CEO Vasant Narasimhan on Transforming a 250-Year-Old Company
Biotech 2050 Podcast
Dec 17
Matt Gline, Roivant Sciences CEO, on Clinical Breakthroughs, Capital Discipline & Building Biotech
Latent Space
Aug 11
🔬The BioAI Phase Shift - Matthew McPartlon & Neil Patil, Chai Discovery
Explore Related Topics
This podcast is featured in Best Business Podcasts (2026) — ranked and reviewed with AI summaries.
Read this week's Health & Longevity Podcast Insights — cross-podcast analysis updated weekly.
You're clearly into In Good Company with Nicolai Tangen.
Every Monday, we deliver AI summaries of the latest episodes from In Good Company with Nicolai Tangen and 192+ other podcasts. Free for one show.
Start My Monday DigestNo credit card · Unsubscribe anytime